Clinical Prevention of Recurrence of Colorectal Adenomas by the Combination of Difluoromethylornithine and Sulindac: An Important Milestone

The spectacular clinical results reported by Meyskens, Gerner and colleagues in a lead article ([1][1]) of this very first issue of this new AACR journal on cancer prevention represent a landmark advance in efforts to stop the current worldwide epidemic of cancer deaths. This study also sets a new,

[1]  Edward S. Kim,et al.  Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial , 2008, Cancer Prevention Research.

[2]  A. D. Macdonald,et al.  The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-κB , 2008, Oncogene.

[3]  A. Pegg,et al.  Polyamines and neoplastic growth. , 2007, Biochemical Society transactions.

[4]  J. Baron,et al.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. , 2006, Gastroenterology.

[5]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[6]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[7]  M. Sporn.  Dichotomies in cancer research: some suggestions for a new synthesis , 2006, Nature Clinical Practice Oncology.

[8]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[9]  E. Gerner,et al.  Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.

[10]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[11]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[12]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[13]  G. Piazza,et al.  Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. , 2000, Cancer research.

[14]  E. Gerner,et al.  Effect of a-Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer Prevention , 1998 .

[15]  M. Sporn,et al.  Recent advances in chemoprevention of cancer. , 1997, Science.

[16]  D. Alberts,et al.  Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. , 1997, Cancer research.

[17]  D. Alberts,et al.  Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. , 1994, Journal of the National Cancer Institute.

[18]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[19]  G. Kelloff,et al.  Chemoprevention of Colon Carcinogenesis by Dietary Administration of Piroxicam, α-Difluoromethylornithine, 16α-Fluoro-5-androsten-17-one, and Ellagic Acid Individually and in Combination , 1991 .

[20]  A. Bull,et al.  Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. , 1986, Journal of the National Cancer Institute.

[21]  M. Sporn.  Combination chemoprevention of cancer , 1980, Nature.

[22]  M. Bertagnolli,et al.  The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. , 1998, Carcinogenesis.